购物车
- 全部删除
- 您的购物车当前为空
Valziflocept (BAX1810; TAK-752)是一种靶向Fc和FcγR的重组可溶性人FcγRIIb受体。该受体通过结合并中和致病IgG发挥作用,充当“诱饵”或“清道夫”,从而有助于缓解自身免疫性疾病如系统性红斑狼疮(SLE)的病情。
Valziflocept (BAX1810; TAK-752)是一种靶向Fc和FcγR的重组可溶性人FcγRIIb受体。该受体通过结合并中和致病IgG发挥作用,充当“诱饵”或“清道夫”,从而有助于缓解自身免疫性疾病如系统性红斑狼疮(SLE)的病情。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | 询价 | 期货 | |
5 mg | 询价 | 期货 |
产品描述 | Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed to act as a "decoy" or "scavenger" by targeting Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigating the impact of autoimmune diseases, making it a focus in systemic lupus erythematosus (SLE) research [1]. |
别名 | TAK-752, BAX1810 |
CAS No. | 1804910-11-9 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容